Trial Profile
A retrospective study comparing post-operative infection risk after arthroplasty in patients with rheumatoid arthritis recieving treatment with abatacept, adalimumab, etanercept, infliximab, tocilizumab or rituximab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 May 2019
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 12 May 2019 Results published in the Annals of Internal Medicine
- 16 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism